The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.
What can we help you find?
Oriahnn is the first FDA-approved nonsurgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women
The FDA recently announced its approval of a vaginal gel that acts as a method of contraception for women. It is the first non-hormonal, vaginal pH regulator contraceptive to be approved by the FDA.
The authors concluded that costs were significantly higher for women with migraines than men and that costs resulting from migraine treatment increased as the patients got older.
Suzanne Soliman, PharmD, BCMAS, Founder and President of Pharmacist Moms, explains why there is a still a need for women to hold positions of leadership in pharmacy, despite the strides in recent years.
Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).
The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.
Although 62% of the first professional degrees in pharmacy were awarded to women in 2017-2018,1 there are only about half as many female pharmacy owners as there are women graduating from pharmacy school.
The newly approved therapy is equivalent to AstraZeneca Pharmaceuticals’ Faslodex injection, 250mg/5mL.
Due to the large number of people affected, chlamydia has become a global health concern.
Attendees at the McKesson ideaShare had the chance to hear about women pharmacists and the challenges, successes, and opportunities they have in a session presented by Suzanne Soliman, PharmD.
The effectiveness and safety of bremelanotide were studied in a pair of 24-week, randomized, double-blind, placebo-controlled trials in 1247 premenopausal women with acquired, generalized HSDD.
A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.